Results 181 to 190 of about 3,752,482 (246)

Recombinant Antibody Vaccines for Targeted Antigen Delivery: Design Principles and Immunological Applications. [PDF]

Vaccines (Basel)
Pirogovsky KM, Hawiger D.
europepmc   +1 more source

Finding novel vulnerabilities of hypomorphic BRCA1 alleles

Molecular Oncology, EarlyView.
Synthetic lethality screens performed to identify novel vulnerabilities often model complete gene loss, thereby overlooking patient‐derived hypomorphic mutations. In this study, we have performed genome‐wide CRISPR screens on BRCA1 hypomorphic mutations, showing BRCA1I26A behaves like wild‐type, while BRCA1R1699Q mimics deficiency. Furthermore, we have
Anne Schreuder, Klaas de Lint, Hồ Mỹ Phúc Võ, Mariana M. Góis, Rosalie A. Kampen, Marta San Martin Alonso, Ilse Nootenboom, Veronica Garzero, Tiemen J. Wendel, Rob M. F. Wolthuis, Sylvie M. Noordermeer   +10 more
wiley   +1 more source

Targeted facet joint surface remodeling for lumbar facet syndrome: A retrospective case series. [PDF]

J Craniovertebr Junction Spine
Nikmaram N, Mostofi K.
europepmc   +1 more source

MITF maintains genome stability in nonmelanocyte lineages

Molecular Oncology, EarlyView.
MITF is essential for melanocyte survival and acts as an oncogene in 10%–20% of melanomas. We show that MITF depletion causes genome instability in nonmelanocytic cells, leading to LATS2‐mediated P53 activation, cell cycle arrest, and apoptosis. This study highlights the role of MITF as a genome maintenance factor beyond the melanocyte lineage. Created
Drifa H. Gudmundsdottir, Adrián López García de Lomana, Thejus B. Venkatesh, Kritika Kirty, Snaevar Sigurdsson, Linda Vidarsdottir, Ramile Dilshat, Erla Sveinbjornsdottir, Snaedis Ragnarsdottir, Daniel H Magnusson, Maria R. Bustos, Eirikur Steingrimsson, Thorkell Gudjonsson, Stefan Sigurdsson   +13 more
wiley   +1 more source

Editorial: Targeted immunological therapies in dermatology

Frontiers in Medicine
Yingrou Tan, Yingrou Tan, Nakamizo Satoshi, Hong Liang Tey, Hong Liang Tey, Hong Liang Tey   +5 more
doaj   +1 more source

Targeting the tumor, harboring the host: IL-7 receptor-targeted CARs to treat T-ALL. [PDF]

Mol Ther Oncol
Kuznetsova V, Kothuru RK, Adusumilli PS, Amador-Molina A.   +3 more
europepmc   +1 more source

A novel quinazolinone insulin receptor inhibitor and its synergy with an EGFR inhibitor in glucose‐driven glioblastoma

Molecular Oncology, EarlyView.
The novel styrylquinazolinone‐based molecule W1B effectively suppresses glioblastoma by inhibiting IGF1R and EGFR. In high‐glucose microenvironments driving tumor resistance, W1B acts synergistically with the EGFR inhibitor dacomitinib. This combination safely blocks compensatory survival signaling in zebrafish xenograft models. Showcasing promising in
Patryk Rurka, Wioleta Cieślik, Wojciech Płaziński, Katarzyna Stępnik, Anna Boguszewska‐Czubara, Elżbieta Kot, Robert Musioł, Mateusz Jasica, Anna Mrozek‐Wilczkiewicz, Katarzyna Malarz   +9 more
wiley   +1 more source

Correction to "Paradigm Guiding to Tapering or Discontinuation of Biologic and Targeted Synthetic Disease-Modifying Antirheumatic Drugs in the Treatment of Patients With Rheumatoid Arthritis: Results From a Local Retrospective Cohort Study". [PDF]

Int J Rheum Dis
europepmc   +1 more source